MJP Associates Inc. ADV Boosts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

MJP Associates Inc. ADV increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.3% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 4,736 shares of the medical research company’s stock after buying an additional 361 shares during the quarter. MJP Associates Inc. ADV’s holdings in Charles River Laboratories International were worth $1,283,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. VisionPoint Advisory Group LLC lifted its position in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Operose Advisors LLC bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $42,000. Brown Brothers Harriman & Co. boosted its stake in shares of Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares during the last quarter. Provence Wealth Management Group bought a new stake in shares of Charles River Laboratories International in the third quarter worth $57,000. Finally, GAMMA Investing LLC purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $62,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Robert W. Baird cut their price target on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. The Goldman Sachs Group started coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They set a “buy” rating and a $290.00 price target on the stock. Mizuho assumed coverage on Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective on the stock. Finally, TD Cowen dropped their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $256.38.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $1.97 on Friday, reaching $211.60. The company’s stock had a trading volume of 681,775 shares, compared to its average volume of 458,894. The company has a market capitalization of $10.90 billion, a price-to-earnings ratio of 24.89, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40. The stock’s fifty day simple moving average is $222.48 and its 200-day simple moving average is $232.55. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. Analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).